WuXi PharmaTech Announces Second-Quarter 2014 Results
PR Newswire - Wed Aug 13, 3:30PM CDT
WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading research and development services company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China and the United States, today announced its financial results for the second quarter of 2014.
WuXi PharmaTech Announces Appointment of Walter Kwauk to Board
PR Newswire - Fri Aug 08, 7:00AM CDT
WuXi PharmaTech (Cayman) Inc. (NYSE:WX), a leading pharmaceutical, biotechnology, and medical device R&D services company with operations in China and the United States, today announced the appointment of Walter Teh-Ming Kwauk as an independent director to the Board of Directors. Mr. Kwauk will serve on the Audit Committee.
WuXi PharmaTech Schedules Second-Quarter 2014 Earnings Release
PR Newswire - Tue Jul 22, 7:00AM CDT
WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology and medical device R&D outsourcing company with operations in China and the United States, today announced that it will release financial results for the second quarter of 2014 after the New York Stock Exchange closes on Wednesday, August 13, 2014 (which will be Thursday morning, August 14, 2014 Shanghai time). The earnings release will be available on the investor relations section of the Company's website at http://www.wuxiapptec.com .
Scheduled Conference Calls and Managements Changes - Analyst Notes on Spectranetics, Charles River, Chemed, WuXi PharmaTech and Ironwood Pharmaceuticals
PR Newswire - Mon Jul 14, 4:40AM CDT
Today, Analysts Review released its analysts' notes regarding The Spectranetics Corporation (NASDAQ: SPNC), Charles River Laboratories (NYSE: CRL), Chemed Corporation (NYSE: CHE), WuXi PharmaTech (Cayman) Inc. (ADR) (NYSE: WX) and Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4742-100free.
Director Ying Han Resigns from WuXi Board
PR Newswire - Tue Jul 08, 3:30PM CDT
WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology, and medical device R&D services company with operations in China and the United States, today announced that Ying Han has stepped down from the WuXi Board of Directors for personal reasons.
5 Foreign Stocks You Need to Sell This Summer
at The Street - Tue Jul 01, 8:57AM CDT
While overseas markets trail the U.S., lots of individual foreign stocks that trade here in the U.S. are looking downright toxic for your portfolio.
Collaborations, Clinical Study Results, and Laboratory Inspection Clearance - Analyst Notes on Amgen, Regeneron, Lexicon, WuXi PharmaTech and ImmunoGen
PR Newswire - Wed Jun 25, 5:40AM CDT
Today, Analysts Review released its analysts' notes regarding Amgen, Inc. (NASDAQ: AMGN), Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX), WuXi PharmaTech (Cayman) Inc. (NYSE: WX) and ImmunoGen, Inc. (NASDAQ: IMGN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4088-100free.
WuXi AppTec Webinar on Breakthrough Drugs Draws Strong Attendance
PR Newswire - Mon Jun 23, 7:00AM CDT
More than 400 life science innovators recently tuned in to a global webinar hosted by WuXi AppTec to gain insights into the advancement of programs that ultimately have been designated by the U.S. Food and Drug Administration as breakthrough therapies. The breakthrough designation applies to specific drugs that treat serious medical conditions and show signs of substantial improvements over available therapies, and it enables their speedy development and commercialization.
WuXi PharmaTech's toxicology facility passes US FDA's GLP compliance and quality services
M2 - Mon Jun 23, 6:02AM CDT
Pharmaceutical company WuXi PharmaTech (Cayman) (NYSE:WX) disclosed on Friday that its Suzhou toxicology facility has passed the US Food and Drug Administration (FDA) Good Laboratory Practice (GLP) inspection, with no major observations.
WuXi PharmaTech Toxicology Facility in Suzhou Passes FDA Inspection
PR Newswire - Fri Jun 20, 7:00AM CDT
WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology, and medical device R&D services company with operations in China and the United States, today announced that its toxicology facility in Suzhou recently passed a surveillance Good Laboratory Practice (GLP) inspection by the U.S. Food and Drug Administration (FDA) with no major observations. This was the first FDA GLP inspection in the facility's five years of operation. The inspection was extensive, lasting five days and including the review of numerous processes and the audit of four studies. WuXi's toxicology facility in Suzhou has completed 92 IND-enabling programs for global submissions.
Health Care Sector Stocks Coverage -- Research on RadNet, IMS Health Holdings, WuXi PharmaTech Cayman, and Ventrus Biosciences
PR Newswire - Wed Jun 18, 6:50AM CDT
On Tuesday, June 17, 2014, the NASDAQ Composite ended at 4,337.23, up 0.37%, the Dow Jones Industrial Average finished the day 0.16% higher at 16,808.49, and the S&P 500 closed at 1,941.99, up 0.22%. During the session five out of ten sectors ended in positive. The S&P 500 Health Care Sector Index ended the day at 688.85, down 0.07%, while the index has advanced 2.52% in the last one month. Investor-Edge has initiated coverage on the following equities: RadNet Inc. (NASDAQ: RDNT), IMS Health Holdings Inc. (NYSE: IMS), WuXi PharmaTech Cayman Inc. (NYSE: WX) and Ventrus Biosciences Inc. (NASDAQ: VTUS). Free technical research on RDNT, IMS, WX and VTUS can be downloaded upon signing up at:
Shares of WX Down 10.1% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Mon Jun 16, 10:06AM CDT
SmarTrend identified a Downtrend for WuXi PharmaTech Cayman (NYSE:WX) on April 8th, 2014 at $34.58. In approximately 2 months, WuXi PharmaTech Cayman has returned 10.13% as of today's recent price of $31.08.
Trade-Ideas: WuXi PharmaTech (WX) Is Today's "Dead Cat Bounce" Stock
at The Street - Mon Jun 16, 9:02AM CDT
Trade-Ideas LLC identified WuXi PharmaTech (WX) as a "dead cat bounce" (down big yesterday but up big today) candidate
WuXi PharmaTech (WX) in Focus: Stock Falls 6.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jun 16, 7:59AM CDT
Shares of WuXi PharmaTech (WX) fell over 6% on the day. This continues the most recent downtrend for WX, as the stock is down nearly 15% since May 22. This recent price action is discouraging, so make sure to keep a close watch on this firm in the near future.
SmarTrend Watching for Potential Rebound in Shares of WuXi PharmaTech Cayman After 6.39% Loss
Comtex SmarTrend(R) - Fri Jun 13, 5:22PM CDT
WuXi PharmaTech Cayman (NYSE:WX) traded in a range yesterday that spanned from a low of $30.41 to a high of $32.76. Yesterday, the shares fell 6.4%, which took the trading range below the 3-day low of $31.11 on volume of 1.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Strategic Collaborations, Certified Solutions, Financial Results, Recognitions, and Commencement of Laboratory Operations - Analyst Notes on Quest Diagnostics, Agilent, Nordion, ICON and WuXi PharmaTech
PR Newswire - Thu Jun 05, 4:40AM CDT
Today, Analysts Review released its analysts' notes regarding Quest Diagnostics Inc. (NYSE: DGX), Agilent Technologies Inc. (NYSE: A), Nordion Inc. (NYSE: NDZ), ICON plc (NASDAQ: ICLR) and WuXi PharmaTech (Cayman) Inc. (NYSE: WX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3397-100free.
WuXi PharmaTech Corporate Venture Fund Invests in TruTag Security Platform for Drug Safety
PR Newswire - Tue Apr 01, 7:00AM CDT
WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology, and medical device R&D services company with operations in China and the United States, and TruTag Technologies, Inc., developer of the leading edible, covert security platform to address the global product counterfeiting challenge, today announced that WuXi Corporate Venture Fund has made an investment in TruTag. In addition, WuXi and TruTag will explore collaborations to offer WuXi's global customers the TruTag on-dose authentication solution to help prevent counterfeiting and to enhance drug safety.
Stocks Turn Mixed, Trade Steady; Facebook Drags On Nasdaq
at Investor's Business Daily - Wed Mar 26, 11:04AM CDT
The market weakened into mixed terrain near midday Wednesday, as the Nasdaq dipped a fraction into negative territory. The S&P 500 held its 0.3% gain and the Dow Jones industrial average was ahead 0.2%. Volume remained higher in the stock market...
Endocyte (ECYT) Soars: Stock Adds 94.4% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 24, 7:51AM CDT
Endocyte, Inc. was a big mover last session, as its shares rose over 94% on the day.
IntelliPharmaCeutics International (IPCI) Soars: Stock Rises 9.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 21, 7:51AM CDT
IntelliPharmaCeutics International Inc. was a big mover last session, as its shares rose over 9% on the day.